Uterine leiomyosarcoma - Pipeline Insight, 2024

Uterine leiomyosarcoma - Pipeline Insight, 2024

DelveInsight’s, “Uterine leiomyosarcoma – Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Uterine leiomyosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Uterine leiomyosarcoma Understanding

Uterine leiomyosarcoma: Overview

A uterine leiomyosarcoma (ULMS) is a rare malignant (cancerous) tumor that arises from the smooth muscle lining the walls of the uterus (myometrium). Leiomyosarcoma is classified as a soft tissue sarcoma. Sarcomas are malignant tumors that arise from the connective tissue, which connects, supports and surrounds various structures and organs in the body. Soft tissue includes fat, muscle, never, tendons, tissue surrounding the joints (synovial tissue), and blood and lymph vessels. The exact cause of leiomyosarcoma, including uterine leiomyosarcoma, is unknown.

Symptoms

Symptoms of uterine leiomyosarcoma may vary from case to case depending upon the exact location, size and progression of the tumor. Many women will not have any apparent symptoms (asymptomatic). The most common symptom is abnormal bleeding from the vagina and the uterus. Postmenopausal bleeding is an important factor that may indicate a uterine leiomyosarcoma. Additional symptoms may occur including pressure or pain affecting the pelvis or stomach, abnormal vaginal discharge, and a change in bladder or bowel habits. General symptoms often associated with cancer include fatigue, fever, weight loss, and a general feeling of ill health (malaise).

Diagnosis

There are no reliable methods to diagnose a uterine LMS before surgery. It is almost always found by chance at the time of a hysterectomy for what was thought to be benign fibroids. There are no specific signs or symptoms, especially in young women. Rapidly changing, or enlarging, fibroids in premenopausal women should be investigated. The vast majority of the time these are not malignant fibroids that are growing in a menopausal woman are concerning and should always be surgical removed.

Treatment

The primary form of treatment for a uterine leiomyosarcoma is surgical removal of the entire tumor and any affected tissue. Total surgical removal of the uterus (hysterectomy) is usually performed. Anti-cancer drugs used alone or combination (chemotherapy) and radiation therapy have been used to treat individuals with leiomyosarcoma following surgery (adjuvant therapy) with limited benefit. Leiomyosarcomas have a high risk of recurrence, individuals should be examined routinely after surgery.

Uterine leiomyosarcoma Emerging Drugs Chapters

This segment of the Uterine leiomyosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Uterine leiomyosarcoma Emerging Drugs

• Trabectedin: PharmMar

Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.

• Letrozole: Novartis

Letrozole is a non-steroidal type II aromatase inhibitor. It blocks the active site, and therefore the electron transfer chain of CYP19A1. This competitive inhibition prevents the conversion of androgens to estrogen. This action leads to a reduction in uterine weight and elevated leuteinizing hormone.8 In postmenopausal women, the action of aromatase is responsible for the majority of estrogen production. With reduced availability of estrogen, estrogen-dependant tumors regress. Third generation aromatase inhibitors do not significantly affect cortisol, aldosterone, and thyroxine levels. Currently, in phase II of clinical trials.

Further product details are provided in the report……..

Uterine leiomyosarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Uterine leiomyosarcoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Uterine leiomyosarcoma

There are approx. 5+ key companies which are developing the therapies for Uterine leiomyosarcoma. The companies which have their Uterine leiomyosarcoma drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Novartis and others.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Uterine leiomyosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Uterine leiomyosarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Uterine leiomyosarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Uterine leiomyosarcoma drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Uterine leiomyosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Uterine leiomyosarcoma.

Uterine leiomyosarcoma Report Insights

• Uterine leiomyosarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Uterine leiomyosarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Uterine leiomyosarcoma drugs?
• How many Uterine leiomyosarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Uterine leiomyosarcoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Uterine leiomyosarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Uterine leiomyosarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• PharmMar

Key Products

• Letrozole
• Trabectedin